Search Results
Your search for The ,The matches 34600 pages
Showing 6901 - 6950ASCO and the European Cancer Organisation to Hold Briefing on Providing Cancer Care During the War in Ukraine
ASCO and the European Cancer Organisation (ECO) will hold a joint session on Friday, March 18, from 9:00–10:00 AM ET, 14:00–15:00 CET, to discuss the current situation of refugees fleeing Ukraine and the impact the war is having on the ability of oncologists in Ukraine, Poland, and Romania to care...
Study Finds Cancer Treatment May Create Employment Difficulties for Some Rural Women
Rural women are likely to face significant challenges finding secure and reliable employment following cancer treatment if they did not already have a secure job at the time of their diagnosis, according to a new study led by University of Arkansas for Medical Sciences (UAMS) researchers. The...
Late Mortality and Life Expectancy After Autologous Blood or Marrow Transplant: Analysis From 1981 to 2014
In an analysis from the BMT Survivor Study reported in the Journal of Clinical Oncology, Smita Bhatia, MD, MPH, and colleagues assessed late mortality over a 30-year period among patients who underwent autologous blood or marrow transplantation (BMT) for hematologic malignancies. They found an...
Nancy Lee, MD: Toward Personalization of Radiotherapy for HPV-Related Oropharyngeal Carcinoma
Nancy Lee, MD, of Memorial Sloan Kettering Cancer Center, discusses results from the 30ROC trial, which showed that intratreatment FMISO [(18)F-fluoromisonidazole] PET response could identify patients with human papillomavirus–positive oropharyngeal carcinoma who may be sensitive to radiation...
Glenn J. Hanna, MD, on Oropharyngeal Squamous Cell Carcinoma: Detecting Occult Recurrence
Glenn J. Hanna, MD, of Dana-Farber Cancer Institute and Harvard Medical School, discusses findings that show human papillomavirus circulating tumor DNA (HPV ctDNA) may be useful as part of surveillance monitoring of patients with oropharyngeal squamous cell carcinoma. Dr. Hanna reports that 93% of...
Gabriel A. Brooks, MPH, MD, Comments on the ACCENT/IDEA Database Analysis Results
Gabriel A. Brooks, MPH, MD, Associate Professor of Medicine, Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, was invited to discuss the results of the ACCENT/IDEA database analysis of early treatment discontinuation in stage III colon cancer.1 Although the results confirm the...
Adjuvant Therapy for Colon Cancer: Impact of Stopping Treatment Early
For patients with stage III colon cancer, early discontinuation of adjuvant chemotherapy leads to worse outcomes—but early discontinuation of oxaliplatin did not. These findings, which came from an analysis of the large ACCENT and IDEA clinical trials databases, were presented at the 2022 ASCO...
Pfizer Announces Plan to Maintain Humanitarian Supply of Medicines to Russians, Donate All Proceeds to Humanitarian Support for the People of Ukraine
On March 14, Pfizer issued the following statement on its company position in Russia. Pfizer stands with the unified global community across the public, private, and civil society sectors in opposition to the Russian war in Ukraine and the brutal situation it has created. The international...
Addition of Bortezomib to Chemotherapy in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma
As reported in the Journal of Clinical Oncology by Teachey et al, the phase III Children’s Oncology Group AALL1231 trial has shown that the addition of bortezomib to a modified augmented Berlin-Frankfurt-Münster (BFM) backbone improved survival outcomes in patients with newly diagnosed T-cell...
Thyroidectomy With or Without Radioiodine for Low-Risk Thyroid Cancer
In the French phase III ESTIMABL2 trial reported in The New England Journal of Medicine, Leboulleux et al found that no use of radioiodine was noninferior to radioiodine ablation in the occurrence of functional, structural, or biologic events among patients undergoing thyroidectomy for low-risk...
New Research Measures Decrease in Cancer Detection Due to the COVID-19 Pandemic
Research published in JNCCN—Journal of the National Comprehensive Cancer Network examined data from the Ontario Cancer Registry from September 25, 2016, through September 26, 2020, to determine the impact of the COVID-19 pandemic on the number of new cancer cases detected. The researchers found...
Sumanta K. Pal, MD, on Advances in Genitourinary Cancer Treatment: Expert Perspective
Sumanta K. Pal, MD, of City of Hope National Medical Center, discusses some key research developments in kidney cancer, including data on nivolumab and ipilimumab with or without CBM588 in metastatic renal cell carcinoma; intestinal microbiome associated with the development of grade 3 or 4 adverse ...
War Is Hell. It’s Also a Public Health Disaster, Especially for People With Cancer
We are all following the ongoing Russian invasion of Ukraine with surprise and horror. I’m sure few readers of The ASCO Post imagined the invasion of a European country by its European neighbor was possible again, naively thinking wars like this ended with the Allied victory in World War II. But...
Novel Radioligand Therapy Improves Progression-Free and Overall Survival in Patients With Metastatic Prostate Cancer
A novel prostate cancer treatment—actinium Ac-225–PSMA-617 radioligand therapy—has been shown to increase the progression-free and overall survival of patients with metastatic castration-resistant prostate cancer, according to research published by Sathekge et al in the Journal of Nuclear Medicine. ...
Racial Genomic Profiles of Primary and Metastatic Breast Cancer
In a study reported in a research letter in JAMA Network Open, Goel et al identified genomic differences among Black, Asian, and White patients with breast cancer and found that Black patients have fewer targetable actionable variants than White patients. Study Details The study included patients...
Factors Contributing to Racial Disparities in the Use of Prostate MRI in Older Patients With Prostate Cancer
In a study reported in JAMA Oncology, Michael S. Leapman, MD, and colleagues found that sociodemographic factors (like geographic area of residence) as well as manifestations of structural racism (like poverty and racial segregation) accounted for the majority of differences in the use of magnetic...
FDA Approves Olaparib for Adjuvant Treatment of High-Risk Early Breast Cancer
On March 11, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza) for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative, high-risk early breast cancer who have been treated with neoadjuvant or adjuvant...
Expert Point of View: Daniel M. Geynisman, MD
Invited discussant Daniel M. Geynisman, MD, of Fox Chase Cancer Center, Philadelphia, found the longer-term follow-up of KEYNOTE-564 “reassuring.” Dr. Geynisman continued: “Following nephrectomy, the goal of adjuvant treatment is to ideally cure or at least significantly delay disease progression....
KEYNOTE-564 Update Supports Benefit of Adjuvant Pembrolizumab in High-Risk Renal Cell Carcinoma
An updated analysis of the phase III KEYNOTE-564 trial continues to support the use of adjuvant pembrolizumab vs placebo in patients with renal cell carcinoma at high risk of recurrence, according to a presentation at the 2022 ASCO Genitourinary Cancers Symposium.1 At 30 months of follow-up,...
First FDA Approval for Neoadjuvant Therapy for Early-Stage NSCLC
In this week’s episode, we’ll discuss a recent U.S. Food and Drug Administration (FDA) approval in the early-stage non–small cell lung cancer setting. Then, we’ll hear about a study presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium that investigated methods for the...
Final Overall Survival Analysis of MONALEESA-2: Addition of Ribociclib to Letrozole in Postmenopausal Women With HR-Positive, HER2-Negative Advanced Breast Cancer
As reported in The New England Journal of Medicine by Gabriel N. Hortobagyi, MD, and colleagues, the protocol-specified final overall survival analysis of the phase III MONALEESA-2 trial has shown a significant benefit with the addition of ribociclib to letrozole in the first-line treatment of...
Study Patients With Dual Medicare and Medicaid Eligibility Have Poorer Outcomes, Higher Spending After Oncologic Surgery
They’re old enough to qualify for Medicare, and their incomes are low enough to qualify them for Medicaid. However, recent research has found that when these “dual eligible” patients have surgery to remove a cancerous tumor, they suffer more complications, stay in the hospital longer, and have a...
Study Shows Structural Racism May Contribute to Poorer Outcomes in Black and Hispanic Patients With Leukemia
Black and Hispanic people with acute myeloid leukemia (AML) in the greater Chicago area were more likely to die from the disease than their non-Hispanic White counterparts, with a 59% and 25% greater risk, respectively, according to a new study led by University of Illinois Chicago researchers. In...
Cancer Risk Among Patients With Pediatric-Onset Inflammatory Bowel Disease
In a meta-analysis of population-based studies reported in JAMA Network Open, Elmahdi et al found that although the reported incidence of cancers in individuals with pediatric-onset inflammatory bowel disease (IBD) is low, the condition is associated with a significantly increased risk of cancers...
Intervention for Racial Disparities in Time to Lung Cancer Surgery: ACCURE Trial
In an analysis from the Accountability for Cancer Care through Undoing Racism and Equity (ACCURE) trial reported in the Journal of Clinical Oncology, Marjory Charlot, MD, MPH, MSc, and colleagues found that the ACCURE intervention reduced the disparity between Black and White patients in time to...
Postoperative Weekly vs Every-3-Week Cisplatin in Chemoradiation for Locally Advanced Head and Neck Cancer
In a Japanese phase II/III trial (JCOG1008) reported in the Journal of Clinical Oncology, Kiyota et al found that overall survival with once-weekly cisplatin in postoperative chemoradiation was noninferior to every-3-week cisplatin for patients with high-risk locally advanced squamous cell...
2023 ACA Proposal Aims to Advance Health Equity and Improve Access to Health-Care Coverage
ASCO submitted comments in response to the Centers for Medicare & Medicaid Services’ (CMS) Patient Protection and Affordable Care Act 2023 Notice of Benefit and Payment Parameters proposed rule. The rule includes proposed changes to standards for issuers and marketplaces and reinstates many...
PREVENT Pandemics Act Would Improve Public Health in the United States
ASCO sent comments to leadership of the U.S. Senate Committee on Health, Education, Labor, and Pensions (HELP) regarding the Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act (PREVENT Pandemics Act). This legislation aims to improve the nation’s public health and...
New ASCO Report Clarifies Potential Value and Utility of Biosimilars in Oncology
A new report from an ASCO expert panel that addresses unanswered questions about biosimilars—licensed biologic products that are largely analogous to products approved by the U.S. Food and Drug Administration (FDA)—found that they may represent an affordable and effective alternative for cancer...
ASCO and Ontario Health Provide Updated Recommendations on Using Adjuvant Bone-Modifying Treatments in Nonmetastatic Breast Cancer
An update to a joint guideline from Cancer Care Ontario (now a division of Ontario Health) and ASCO provides revised recommendations for the use of adjuvant bone-modifying agents for patients with nonmetastatic breast cancer, with the overarching goal of improving relapse and survival rates.1,2...
The Virtues of Ruth: Gratitude, Advocacy, and Service
I still remember having to sit down with her three siblings on that afternoon. It was drizzling, cloudy, and cool—Mother Nature in agreement with the heaviness of what had just taken place. I held them tight. I knew the words I would utter next would change their lives forever. I paused for 10...
Importing Oncology Trials From China, or Other Single Foreign Countries, for Consideration of U.S. Regulatory Approvals
In a commentary published recently in The Lancet Oncology,1 Harpreet Singh, MD, and Richard Pazdur, MD, both of the Oncology Center of Excellence at the U.S. Food and Drug Administration (FDA), warned against the increasing number of oncology drug development programs based wholly or predominantly...
Managing Long-Term Toxicity From Pelvic Radiation Therapy
Advances over the past 3 decades in improvements in cancer prevention and screening strategies and more effective diagnostics and therapies in cancer care have led to unprecedented declines in death rates from all cancers, including prostate, gynecologic, and colorectal/anal cancers. The fastest...
Project Confirm: An Initiative to Promote Transparency of the Accelerated Approval Program for Oncology Indications
OCE Insights is an occasional column developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Gautam U. Mehta, MD, Neurosurgical Oncologist and Clinical Reviewer, Division of Oncology 2; Fatima Rizvi,...
The Road to a Career in Breast Oncology Took Several Twists and Turns for Sara A. Hurvitz, MD, FACP
Breast cancer specialist Sara A. Hurvitz, MD, FACP, grew up in the East Bay area of Northern California, the youngest of five children. “My mother was a traditional stay-at-home mom, and my father was a probation officer. I come from a long line of artists; my great-grandfather on my mother’s side...
Time for a Radical Change in the Treatment of Endometrial Cancer: KEYNOTE-775 and Beyond
I had the privilege of sitting in a meeting on the treatment of endometrial cancer as a junior investigator in January 2015 where a representative from the U.S. Food and Drug Administration was present. The topic of the meeting was on how to design the next endometrial cancer trials. I remember...
Lenvatinib/Pembrolizumab Improves Progression-Free and Overall Survival vs Chemotherapy in Previously Treated Advanced Endometrial Cancer
As reported in The New England Journal of Medicine by Vicky Makker, MD, of Memorial Sloan Kettering Cancer Center, and colleagues, the phase III Study 309/KEYNOTE-775 trial has shown prolonged progression-free and overall survival with lenvatinib plus pembrolizumab vs physician’s choice of...
Expert Point of View: Priyanka Sharma, MD
Priyanka Sharma, MD, of the University of Kansas Medical Center in Westwood, the invited discussant of the poster, noted that the DAISY study asked whether HER2-targeted antibody-drug conjugates—in this case, fam-trastuzumab deruxtecan-nxki (T-DXd)—have activity beyond the conventional...
T-DXd Shows Activity in HER2-Low, HER2-Undetectable Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) has led to practice changes in previously treated HER2-positive metastatic breast cancer. Most notably, in the DESTINY-Breast03 trial, treatment with T-DXd produced a doubling in 12-month progression-free survival vs...
Clinical Trials Underway for T-DXd in Breast Cancer
The current standard of care for the neoadjuvant treatment of HER2-positive early-stage breast cancer consists of trastuzumab plus pertuzumab and polychemotherapy. But some patients, particularly those with locally advanced or inflammatory disease, still relapse and die. Furthermore, multiagent...
ABC Sixth International Consensus Conference Updates Guidelines for Advanced Breast Cancer
New recommendations for treating advanced breast cancer, coming from a panel of experts at the Advanced Breast Cancer (ABC) Sixth International Consensus Conference (ABC6), were recently published.1 The report highlights advances that have resulted in robust improvements in overall survival for...
Margaret von Mehren, MD, Appointed New Vice Chair of Department of Hematology/Oncology at Fox Chase
Margaret von Mehren, MD, Chief of the Division of Sarcoma Medical Oncology at Fox Chase Cancer Center, was recently appointed the new Vice Chair of the Department of Hematology/Oncology. “It is an honor to serve the Department of Hematology and Oncology, which I have been a member of since 1993,...
Iberia Romina Sosa, MD, PhD, Appointed New Chief of Division of Hematology at Fox Chase
Iberia Romina Sosa, MD, PhD, Associate Professor at Fox Chase Cancer Center, was recently appointed as the new Chief of the Division of Hematology in the Department of Hematology/Oncology. “I feel truly privileged to have been offered this role and to have the opportunity to work with such a...
Expert Point of View: Mikkael A. Sekeres, MD
Mikkael A. Sekeres, MD, Professor of Medicine and Chief of the Division of Hematology, Sylvester Comprehensive Cancer Center of the University of Miami Miller School of Medicine, said the “fascinating” findings of the study reported by Bouzid et al make it worthy of an ASH Plenary Session...
CHIP Mutations ‘Surprisingly’ Associated With Lower Risk of Alzheimer’s Disease
The presence of clonal hematopoiesis of indeterminate potential, or CHIP, increases the risk of developing a myeloid malignancy and also cardiovascular disease—which are well-established findings—but it may also protect against developing Alzheimer’s disease, according to findings reported at the...
Memorial Sloan Kettering President and Chief Executive Officer, Craig B. Thompson, MD, to Step Down
Craig B. Thompson, MD, announced his intention to step down as President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center (MSK) and has asked the Boards of Trustees and Governing Trustees to begin a search for his successor. Dr. Thompson will continue in his role until the...
Expert Point of View: Matthew Genyeh Mei, MD
American Society of Hematology (ASH) session co-moderator Matthew Genyeh Mei, MD, Associate Professor, Hematologic Malignancies and Stem Cell Transplantation Institute of City of Hope in Southern California, said the studies of checkpoint inhibitors in newly diagnosed and previously treated Hodgkin ...
Combinations Advance the Power of Pembrolizumab in Hodgkin Lymphoma
Pembrolizumab monotherapy is an established treatment strategy for relapsed or refractory classical Hodgkin lymphoma. In combination with chemotherapy, the checkpoint inhibitor is also showing value in the front-line setting and further boosting outcomes in the relapsed setting, according to...
Laura Bukavina, MD, MPH, Wins ASCO Genitourinary Conquer Cancer Merit Award for Microbiome Research in Bladder Cancer
Laura Bukavina, MD, MPH, a Urologic oncology fellow at Fox Chase Cancer Center, has been awarded the ASCO Genitourinary Conquer Cancer Merit Award. She presented the winning abstract, which characterizes the gut microbiome of patients with bladder cancer, at the 2022 ASCO Genitourinary (GU) Cancers ...
American Cancer Society Reports Breast Cancer Is Now the Leading Cause of Cancer Mortality in Black Women
Breast cancer has surpassed lung cancer as the leading cause of cancer mortality among Black women as of 2019. This news is one of the key findings in Cancer Statistics for African American/Black People 2022, published recently in CA: A Cancer Journal for Clinicians and its consumer-friendly...
